$DMN
Damon Inc. Stock $dmn

$dmn Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000121390024109877 Filed on December 18, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2024 Q2
Revenue		$102.0K	$0.00
YoY Change
Cost Of Revenue		$39.65K
YoY Change		66.55%
Gross Profit		$62.32K
YoY Change		-15.9%
Gross Profit Margin		61.12%
Selling, General & Admin		$267.9K	$10.53M
YoY Change		-92.04%	-41.2%
% of Gross Profit		429.92%
Research & Development			$1.554M
YoY Change			-82.99%
% of Gross Profit
Depreciation & Amortization		$253.00	$223.3K
YoY Change		-99.68%	-39.75%
% of Gross Profit		0.41%
Operating Expenses		$1.483M	$10.14M
YoY Change		-62.41%	-62.96%
Operating Profit		-$1.420M
YoY Change		38373.62%
Interest Expense			-$2.204M
YoY Change			102.41%
% of Operating Profit
Other Income/Expense, Net		-$144.1K	-$19.26M
YoY Change		-87.4%	346.4%
Pretax Income		-$1.565M	-$33.97M
YoY Change		-70.9%	-8.23%
Income Tax
% Of Pretax Income
Net Earnings		-$1.565M	-$33.97M
YoY Change		-70.9%	-8.23%
Net Earnings / Revenue		-1534.33%
Basic Earnings Per Share		-$0.39
Diluted Earnings Per Share		-$0.39	-$1.64
COMMON SHARES
Basic Shares Outstanding	20.77M shares	4.007M shares
Diluted Shares Outstanding		4.007M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$395.6K
YoY Change
Cash & Equivalents	$175.3K	$1.149M
Short-Term Investments
Other Short-Term Assets	$24.61K	$90.92K
YoY Change
Inventory
Prepaid Expenses	$76.72K	$70.49K
Receivables	$55.87K	$30.57K
Other Receivables
Total Short-Term Assets	$1.240M	$486.5K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment	$2.276K	$1.138M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$265.00	$126.4K
YoY Change
Total Long-Term Assets	$2.541K	$1.265M
YoY Change
TOTAL ASSETS
Total Short-Term Assets	$1.240M	$486.5K
Total Long-Term Assets	$2.541K	$1.265M
Total Assets	$1.243M	$1.751M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$972.1K	$3.172M
YoY Change
Accrued Expenses	$104.5K	$3.195M
YoY Change
Deferred Revenue	$151.4K	$144.4K
YoY Change
Short-Term Debt		$40.63M
YoY Change
Long-Term Debt Due		$1.107M
YoY Change
Total Short-Term Liabilities	$1.228M	$51.79M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt		$177.4K
YoY Change
Other Long-Term Liabilities		$235.5K
YoY Change
Total Long-Term Liabilities		$412.9K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.228M	$51.79M
Total Long-Term Liabilities		$412.9K
Total Liabilities	$3.202M	$52.20M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings	-$3.319M	-$1.755M
YoY Change
Common Stock	$1.371M	$1.307M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.959M	-$50.45M
YoY Change
Total Liabilities & Shareholders Equity	$1.243M	$1.751M
YoY Change

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$1.565M	-$33.97M
YoY Change	-70.9%	-8.23%
Depreciation, Depletion And Amortization	$253.00	$223.3K
YoY Change	-99.68%	-39.75%
Cash From Operating Activities	-$799.5K	-$8.569M
YoY Change	-81.41%	-59.35%
INVESTING ACTIVITIES
Capital Expenditures		$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$596.0K	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$41.64K
YoY Change		-97.93%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$414.3K	6.270M
YoY Change	-91.59%	-54.67%
NET CHANGE
Cash From Operating Activities	-$799.5K	-8.569M
Cash From Investing Activities	-$596.0K	0.000
Cash From Financing Activities	$414.3K	6.270M
Net Change In Cash	-$973.6K	-2.300M
YoY Change	-255.52%	-71.36%
FREE CASH FLOW
Cash From Operating Activities	-$799.5K	-$8.569M
Capital Expenditures		$0.00
Free Cash Flow		-$8.569M
YoY Change		-59.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q3	dei	Document Type DocumentType	10-Q
CY2024Q3	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q3	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
CY2024Q3	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q3	dei	Entity File Number EntityFileNumber	001-42190
CY2024Q3	dei	Entity Registrant Name EntityRegistrantName	DAMON INC.
CY2024Q3	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
CY2024Q3	dei	Entity Address Address Line1 EntityAddressAddressLine1	704 Alexander Street
CY2024Q3	dei	Entity Address City Or Town EntityAddressCityOrTown	Vancouver
CY2024Q3	dei	Entity Address State Or Province EntityAddressStateOrProvince	BC
CY2024Q3	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V6A 1E3
CY2024Q3	dei	City Area Code CityAreaCode	(408)
CY2024Q3	dei	Local Phone Number LocalPhoneNumber	702-2167
CY2024Q3	dei	Security12b Title Security12bTitle	Common Shares
CY2024Q3	dei	Trading Symbol TradingSymbol	DMN
CY2024Q3	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q3	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q3	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q3	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q3	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q3	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q3	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q3	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20767610	shares
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	175292	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1148904	usd
CY2024Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	55865	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30572	usd
CY2024Q3	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	238103	usd
CY2024Q2	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	108568	usd
CY2024Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	907897	usd
CY2024Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	441432	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	76721	usd
CY2024Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	70487	usd
CY2024Q3	us-gaap	Other Assets Current OtherAssetsCurrent	24614	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	548	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	1240389	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	1691943	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2276	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2392	usd
CY2024Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	265	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	251	usd
CY2024Q3	us-gaap	Assets Assets	1242930	usd
CY2024Q2	us-gaap	Assets Assets	1694586	usd
CY2024Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	972125	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	440688	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	104513	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59921	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	151377	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	144390	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1228015	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	644999	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	1974316	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	1506561	usd
CY2024Q3	us-gaap	Liabilities Liabilities	3202331	usd
CY2024Q2	us-gaap	Liabilities Liabilities	2151560	usd
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4615384	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4615384	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3600001	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3600001	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	743637	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	679302	usd
CY2024Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	627478	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	627478	usd
CY2024Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-11050	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8828	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-3319466	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1754926	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1959401	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-456974	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1242930	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1694586	usd
CY2024Q3	us-gaap	Revenues Revenues	101969	usd
CY2023Q3	us-gaap	Revenues Revenues	97908	usd
CY2024Q3	us-gaap	Cost Of Revenue CostOfRevenue	39647	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	23805	usd
CY2024Q3	us-gaap	Gross Profit GrossProfit	62322	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	74103	usd
CY2024Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	43322	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	44587	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	224614	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33208	usd
CY2024Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1085297	usd
CY2024Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	129535	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	1482768	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	77795	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1420446	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3692	usd
CY2024Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	168160	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	24066	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-144094	usd
CY2024Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1564540	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3692	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1564540	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3692	usd
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.39
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.001
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.001
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4006706	shares
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4006706	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3600001	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3600001	shares
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1564540	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3692	usd
CY2024Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2222	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1082	usd
CY2024Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1566762	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4774	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	202388	usd
CY2023Q3	dmn	Net Investments From Inpixon NetInvestmentsFromInpixon	32193	usd
CY2023Q3	us-gaap	Cumulative Translation Adjustment Net Of Tax Period Increase Decrease CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	-1082	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3692	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	229807	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-456974	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	64335	usd
CY2024Q3	us-gaap	Cumulative Translation Adjustment Net Of Tax Period Increase Decrease CumulativeTranslationAdjustmentNetOfTaxPeriodIncreaseDecrease	-2222	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1564540	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1959401	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1564540	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3692	usd
CY2024Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	253	usd
CY2023Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	216	usd
CY2024Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	82178	usd
CY2024Q3	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses	129535	usd
CY2024Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	24066	usd
CY2024Q3	dmn	Accrued Interest Expense AccruedInterestExpense	50405	usd
CY2024Q3	dmn	Accrued Monitoring Fee Expense AccruedMonitoringFeeExpense	35577	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23541	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-47626	usd
CY2024Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3068	usd
CY2023Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	149	usd
CY2024Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	528078	usd
CY2023Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	958	usd
CY2024Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-9058	usd
CY2023Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4830	usd
CY2024Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1288	usd
CY2023Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	17156	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-799535	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	57285	usd
CY2024Q3	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable	596000	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-596000	usd
CY2024Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	350000	usd
CY2024Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	64335	usd
CY2023Q3	dmn	Proceeds From Net Investments From Inpixon ProceedsFromNetInvestmentsFromInpixon	32193	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	414335	usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32193	usd
CY2024Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7588	usd
CY2023Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-5308	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-973612	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	84170	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1148904	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	264244	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	175292	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	348414	usd
CY2024Q3	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note 1 - Organization and Nature of Business</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Damon Inc. (formerly known as Grafiti Holding Inc. (“Grafiti Holding”)) (collectively with its subsidiaries, as appropriate, “Damon”, the “Company,” “we,” “us” or “our”) was incorporated in British Columbia, Canada on October 17, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Grafiti Limited (formerly known as “Inpixon Limited”) was incorporated in England and Wales on May 13, 2020. Grafiti Limited provides specialized scientific software products and services for the environmental sciences, life sciences, behavioral sciences, medical research and engineering domains. Grafiti Limited provides effective solutions to the scientific and engineering community to compress the time intensive process of data analysis and presentation, thus enhancing productivity. Users of Grafiti Limited’s products include government organizations, academic institutions and leading corporations. Grafiti Limited’s headquarters are located in Slough, United Kingdom, and operations for Grafiti Limited are primarily performed in the United Kingdom.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 23, 2023, a Business Combination Agreement (as amended by the First Amendment to the Business Combination Agreement dated June 18, 2024 and the Second Amendment to the Business Combination Agreement dated September 26, 2024, the “Damon Business Combination Agreement”) was entered into by and among XTI Aerospace Inc., formerly known as “Inpixon” (“Inpixon,” or “Parent”), the Company, 1444842 B.C. LTD (“Amalco Sub”), and Damon Motors, Inc. (“Damon Motors”), pursuant to which Damon Motors will amalgamate with Amalco Sub, a British Columbia corporation and a wholly-owned subsidiary of the Company, with Damon Motors continuing as the surviving entity and a wholly-owned subsidiary of the Company (the “Business Combination”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Additionally, pursuant to a Separation and Distribution Agreement, dated October 23, 2023, between Inpixon and the Company, Inpixon contributed the assets and liabilities of Grafiti Limited, a wholly owned subsidiary of Inpixon, to the Company, the then Inpixon wholly owned subsidiary. As a result, the Company became the parent non-operating holding company of Grafiti Limited. In connection with the spin-off of the Company from Inpixon as contemplated by the Business Combination Agreement (“Grafiti Holding Spin-off”), on December 27, 2023 (the “record date”), Inpixon transferred the Company’s common shares to a newly-created liquidating trust, titled the Grafiti Holding Inc. Liquidating Trust (the “Trust”), which holds the Company’s common shares for the benefit of the holders of Inpixon common stock, preferred stock and those outstanding warrants that are contractually entitled to participate in the distribution of the Company’s common shares, on a pro rata basis as of the record date (the “participating Inpixon securityholders”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of December 26, 2023, pursuant to the Separation and Distribution Agreement, Grafiti Limited was assigned by Inpixon to the Company. The Company consolidates Grafiti Limited via the voting interest model, as Grafiti Limited is wholly owned by the Company. This transaction between entities under common control resulted in a change in reporting entity and required retrospective combination of the entities for all periods presented, as if the combination had been in effect since the inception of common control. Accordingly, the financial statements of the Company reflect the accounting of the combined acquired subsidiary at historical carrying values except that equity reflects the equity of the Company. This change in reporting entity did not impact net income for the periods presented. Pursuant to a Liquidating Trust Agreement, dated December 27, 2023, among Inpixon, the Company and the initial trustee of the Trust, the Company common shares were to be held by the Trust until the registration statement on Form 10-12B filed for the spin-off (the “Registration Statement”) had been declared effective by the Securities and Exchange Commission (the “SEC”). Promptly following the effective time of the Registration Statement, the Trust will deliver the Company’s common shares to the participating Inpixon security holders, as beneficiaries of the Trust, pro rata in accordance with their ownership of shares or underlying shares of Inpixon common stock as of the record date.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On November 12, 2024, the Trust shares were delivered to participating Parent securityholders, and on November 13, 2024, Damon Motors and Amalco Sub amalgamated to continue as a wholly owned subsidiary of the Company (the “Amalgamation”). Following the Amalgamation, the Company was renamed “Damon Inc.” (also referred to herein as the “combined company”). The common shares of the combined company are listed on the Nasdaq Global Market under the ticker symbol “DMN”. The Company incurred $1,085,297 of acquisition related costs related to the Damon Business Combination Agreement during the three months ended September 30, 2024. These costs are included in the acquisition-related costs line in the condensed consolidated statements of operations. See Note 14.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying condensed consolidated financial statements of the Company, show the historical financial position, results of operations, changes in stockholders’ deficit and cash flows of the Company. Prior to December 27, 2023, the Company operated as a segment of Inpixon and not as a separate entity. The operating results of the Company prior to December 27, 2023 have been specifically identified by Inpixon’s management based on the Company’s existing divisional organization and are presented on a carve-out basis. The historical costs and expenses reflected in our condensed consolidated financial statements prior to December 27, 2023 include an allocation by time spent for certain corporate and shared service functions. See Note 11 for further additional information regarding the Investments by Inpixon prior to December 27, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management believes the assumptions underlying our condensed consolidated financial statements are reasonable but may not necessarily be indicative of the costs that would have incurred if the Company had been operated on a standalone basis for the entire periods presented. Actual costs that would have been incurred if we had operated as a standalone company for the entirety of the periods presented would depend on multiple factors, including organizational structure and strategic decisions made in various areas, including information technology and infrastructure. The Company also may incur additional costs associated with being a standalone, publicly listed company that were not included in the expense allocations, prior to December 27, 2023, and therefore, would result in additional costs that are not reflected in our historical results of operations, financial position and cash flows.</p>
CY2024Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1085297	usd
CY2024Q3	dmn	Working Capital WorkingCapital	12374	usd
CY2024Q3	us-gaap	Cash Cash	175292	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-1564540	usd
CY2024Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-799535	usd
CY2024Q3	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during each of the reporting periods. Actual results could differ from those estimates. The Company’s significant estimates consist of:</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">the allowance for credit losses;</td></tr></table><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.5in"></td><td style="width: 0.25in">●</td><td style="text-align: justify">the valuation allowance for deferred tax assets.</td></tr></table>
CY2024Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	907897	usd
CY2024Q3	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	238103	usd
CY2024Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	441432	usd
CY2024Q2	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	108568	usd
CY2024Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	151377	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	144390	usd
CY2024Q3	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	57618	usd
CY2024Q3	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year amounts have been reclassified to conform to September 30, 2024 presentation. The Company notes that these reclassifications only impacted the balance sheet and did not impact cash flows or net loss.</p>
CY2024Q3	us-gaap	Revenues Revenues	101969	usd
CY2023Q3	us-gaap	Revenues Revenues	97908	usd
CY2024Q3	us-gaap	Revenues Revenues	101969	usd
CY2023Q3	us-gaap	Revenues Revenues	97908	usd
CY2024Q2	us-gaap	Loans Assumed1 LoansAssumed1	200000	usd
CY2024Q3	us-gaap	Loans Assumed1 LoansAssumed1	596000	usd
CY2024Q3	us-gaap	Interest Income Other InterestIncomeOther	24066	usd
CY2023Q3	us-gaap	Interest Income Other InterestIncomeOther	0	usd
CY2024Q3	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	1146000	usd
CY2024Q2	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	550000	usd
CY2024Q3	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	238103	usd
CY2024Q2	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	108568	usd
CY2024Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	907897	usd
CY2024Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	441432	usd
CY2024Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	907897	usd
CY2024Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	441432	usd
CY2024Q3	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	907897	usd
CY2024Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	441432	usd
CY2024Q2	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	108568	usd
CY2024Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	129535	usd
CY2024Q3	us-gaap	Allowance For Notes And Loans Receivable Current AllowanceForNotesAndLoansReceivableCurrent	238103	usd
CY2024Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	17326	usd
CY2024Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	19780	usd
CY2024Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3921	usd
CY2024Q2	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	3708	usd
CY2024Q3	us-gaap	Interest Payable Current InterestPayableCurrent	53706	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	3301	usd
CY2024Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	18390	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	17393	usd
CY2024Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	11170	usd
CY2024Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	15739	usd
CY2024Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	104513	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59921	usd
CY2024Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	6470000	usd
CY2024Q1	us-gaap	Long Term Debt Description LongTermDebtDescription	The Streeterville Note carries an original issue discount of $1,450,000 and $20,000 of issuance costs to cover legal, accounting, due diligence, monitoring and other transaction costs. On the same day, the Investor paid the purchase price of $5,000,000 as follows: (a) $1,150,000 to the Company; (b) $350,000 to Damon Motors as a senior secured loan from the Company to Damon Motors (the “Grafiti Holding Note”), and (c) $3,500,000 into escrow, which will be distributed to the Company upon satisfaction of certain conditions including
CY2024Q1	dmn	Investor Purchase Amount Received InvestorPurchaseAmountReceived	5000000	usd
CY2024Q1	us-gaap	Escrow Deposit EscrowDeposit	3500000	usd
CY2024Q3	us-gaap	Escrow Deposit EscrowDeposit	350000	usd
CY2024Q4	us-gaap	Escrow Deposit EscrowDeposit	3150000	usd
CY2024Q3	us-gaap	Long Term Debt LongTermDebt	1974316	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	1506561	usd
CY2024Q3	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	101500	usd
CY2024Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	50405	usd
CY2024Q3	dmn	Amortized Debt Discount AmortizedDebtDiscount	82178	usd
CY2024Q3	dmn	Monitoring Fee Amortization MonitoringFeeAmortization	35577	usd
CY2024Q3	dmn	Percentage Of Exercise Price PercentageOfExercisePrice	1.10	pure
CY2024Q3	dmn	Percentage Of Outstanding Common Shares PercentageOfOutstandingCommonShares	0.10	pure
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	0	usd
CY2024Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	0	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1015383	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	64335	usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1015383	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.06336
CY2024Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1015383	shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.06336
CY2023Q3	dmn	Net Investments From Inpixon NetInvestmentsFromInpixon	32193	usd
CY2024Q4	us-gaap	Common Stock Shares Held In Employee Trust Shares CommonStockSharesHeldInEmployeeTrustShares	3536746	shares
CY2024Q3	dmn	Common Stock Subordinate Voting Shares CommonStockSubordinateVotingShares	14761045	shares
CY2024Q3	us-gaap	Warrant Exercise Price Increase WarrantExercisePriceIncrease	7.81
CY2024Q3	us-gaap	Stock Option Exercise Price Decrease StockOptionExercisePriceDecrease	0.57
CY2024Q3	us-gaap	Stock Option Exercise Price Increase StockOptionExercisePriceIncrease	12.73
CY2024Q4	dmn	Aggregate Principal Amount AggregatePrincipalAmount	6470000	usd
CY2024Q4	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	8385000	usd
CY2024Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1885000	usd
CY2025Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2000000	usd
CY2025Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1500000	usd
CY2025Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1500000	usd
CY2025Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1500000	usd
CY2024Q3	dmn	Initial Maturity Date InitialMaturityDate	P18M
CY2024Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1
CY2024Q3	dmn	Additional Issued Discount Per Share AdditionalIssuedDiscountPerShare	0.29
CY2024Q3	srt	Interest Bearing Liabilities Average Rate Paid InterestBearingLiabilitiesAverageRatePaid	0.10	pure
CY2025Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2000000	usd
CY2025Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1500000	usd
CY2025Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1500000	usd
CY2025Q3	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1500000	usd
CY2024Q3	dmn	Non Rule10b51 Arrangement Modified Flag NonRule10b51ArrangementModifiedFlag	false
CY2024Q3	dmn	Rule10b51 Arrangement Modified Flag Rule10b51ArrangementModifiedFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q3	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q3	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q3	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2024Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q3	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2024	us-gaap	Common Stock Shares Authorized Unlimited CommonStockSharesAuthorizedUnlimited	Unlimited
CY2023Q3	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts		usd
CY2023Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023Q3	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating		usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest		usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2023Q3	us-gaap	Provision For Other Credit Losses ProvisionForOtherCreditLosses		usd
CY2023Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
CY2023Q3	dmn	Accrued Interest Expense AccruedInterestExpense		usd
CY2023Q3	dmn	Accrued Monitoring Fee Expense AccruedMonitoringFeeExpense		usd
CY2023Q3	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable		usd
CY2023Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
CY2023Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2024Q3	dmn	Proceeds From Net Investments From Inpixon ProceedsFromNetInvestmentsFromInpixon		usd
CY2024Q3	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q3	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q3	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Interest Expense InterestExpense		usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings		usd
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q3	dmn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueGranted		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2024Q3	dmn	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Expired ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValueExpired		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2024Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2024Q3	dmn	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Valu Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValuForfeitures		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber		shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber		shares
CY2024Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
CY2024Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2024Q3	dei	Amendment Flag AmendmentFlag	false
CY2024Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q3	dei	Entity Central Index Key EntityCentralIndexKey	0002000640

Files In Submission

Name	View Source	Status
0001213900-24-109877-index-headers.html	Edgar Link	pending
0001213900-24-109877-index.html	Edgar Link	pending
0001213900-24-109877.txt	Edgar Link	pending
0001213900-24-109877-xbrl.zip	Edgar Link	pending
dmn-20240930.xsd	Edgar Link	pending
ea0224015-10q_damon.htm	Edgar Link	pending
ea022401501ex3-1_damon.htm	Edgar Link	pending
ea022401501ex31-1_damon.htm	Edgar Link	pending
ea022401501ex31-2_damon.htm	Edgar Link	pending
ea022401501ex32-1_damon.htm	Edgar Link	pending
ex3-1_001.jpg	Edgar Link	pending
ex3-1_002.jpg	Edgar Link	pending
ex3-1_003.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
dmn-20240930_cal.xml	Edgar Link	unprocessable
dmn-20240930_def.xml	Edgar Link	unprocessable
dmn-20240930_lab.xml	Edgar Link	unprocessable
dmn-20240930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ea0224015-10q_damon_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DMN
Damon Inc. Stock $dmn

2024 Q4 Form 10-Q Financial Statement

#000121390024109877 Filed on December 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMN Damon Inc. Stock $dmn

2024 Q4 Form 10-Q Financial Statement

#000121390024109877 Filed on December 18, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DMN
Damon Inc. Stock $dmn